Sanofi (France) Starts Dengue Vaccine Production to Keep Lead Over Rivals
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
Sanofi SA has started producing its experimental dengue vaccine, the most advanced against the tropical disease, in a move to keep its lead over competitors ahead of the product's likely launch in 2015. The mosquito-borne disease is a threat to nearly 3 billion people and is caused by four types of virus, none of which confers immunity from the others. Sanofi's vaccine could generate sales of over $1 billion if successful. Guillaume Leroy, who heads the dengue vaccine project at Sanofi Pasteur, the French group's vaccine unit, told reporters the group would be able to supply 100 million doses a year. Sanofi Pasteur, which has been working on the project for 20 years, has kick-started production ahead of receiving authorization from regulators to ensure it will be the first company to launch this type of vaccine.
Help employers find you! Check out all the jobs and post your resume.
Sanofi SA has started producing its experimental dengue vaccine, the most advanced against the tropical disease, in a move to keep its lead over competitors ahead of the product's likely launch in 2015. The mosquito-borne disease is a threat to nearly 3 billion people and is caused by four types of virus, none of which confers immunity from the others. Sanofi's vaccine could generate sales of over $1 billion if successful. Guillaume Leroy, who heads the dengue vaccine project at Sanofi Pasteur, the French group's vaccine unit, told reporters the group would be able to supply 100 million doses a year. Sanofi Pasteur, which has been working on the project for 20 years, has kick-started production ahead of receiving authorization from regulators to ensure it will be the first company to launch this type of vaccine.
Help employers find you! Check out all the jobs and post your resume.